Nizar Attallah, MD
Nephrology · Louisville, KYNPI 1952333908
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,595 of the $112,988 with a category attached, or 81.1%. Boehringer Ingelheim accounts for 62.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $74,199 and has fallen 58.8% since, to $30,571 in 2025. Among nephrology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $582.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$71K
- Lilly USA, LLC$40K
- Fresenius USA Marketing, Inc.$480
- AstraZeneca$200
- Otsuka America Pharmaceutical, Inc.$162
- Abbott$139
- plus $886 from 12 others
What the payments were for
- Consulting fees$5,7605%
- Speaking & faculty fees$91,59581%
- Travel & lodging$12,22811%
- Food & beverage$3,3823%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 66 | $70,745 |
| Lilly USA, LLC | 36 | $40,377 |
| Fresenius USA Marketing, Inc. | 27 | $480 |
| AstraZeneca(2 entities) | 12 | $200 |
| Otsuka America Pharmaceutical, Inc. | 8 | $162 |
| Abbott | 1 | $139 |
| Vifor Pharma, Inc. | 7 | $136 |
| Amgen(2 entities) | 6 | $133 |
| Novartis | 7 | $126 |
| Travere Therapeutics, Inc. | 7 | $121 |
| Nxstage Medical, Inc. | 1 | $117 |
| GSK | 5 | $73 |
| Ardelyx, Inc. | 3 | $49 |
| Bayer | 3 | $45 |
| Novo Nordisk | 2 | $33 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$106,768
- CARDIOMEMS$139
- MOUNJARO$120
- NXSTAGE SYSTEM ONE$117
- LIBERTY SELECT CYCLER$117
How this compares
$112,988 in reported general payments places this provider in the 95th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 122 | $121,760 |
| FarxigaDapagliflozin Propanediol | 14 | $19,231 |
| Valganciclovir Hcl | 16 | $12,938 |
| Cinacalcet Hcl | 22 | $2,499 |
| Calcium Acetate | 17 | $1,459 |
| Metoprolol Succinate | 56 | $1,125 |
| Hydralazine Hcl | 87 | $1,054 |
| Losartan Potassium | 190 | $1,024 |
| Torsemide | 34 | $782 |
| Bumetanide | 15 | $698 |
| Doxazosin Mesylate | 26 | $633 |
| Amlodipine Besylate | 91 | $585 |
| Nifedipine ErNifedipine | 34 | $563 |
| Calcitriol | 44 | $483 |
| Rosuvastatin Calcium | 21 | $425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $70,745 | $121,760122 claims |
| AstraZenecaFarxiga | $200 | $19,23114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 nephrology providers in Kentucky.
Other nephrology in Louisville
- Danny WooLouisville$427K
- Dawn CasterLouisville$193K
- Shafic Abdul Wahab El HindiLouisville$45K
- George AronoffLouisville$26K
- Jai BhimaniLouisville$10K
- Alexander AfanasyevLouisville$10K
- William DuffLouisville$9K
- Bhagwan BhimaniLouisville$7K
- Aziz ChamiLouisville$6K
- John GleasonLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.